Supportive care remains the backbone of dengue treatment, reflecting the absence of approved antiviral therapies. For most patients, management involves rest, oral fluids, and fever control with acetaminophen. For patients with warning signs or severe dengue, hospitalisation and intravenous fluid therapy are essential to manage plasma leakage and prevent shock. The quality and timeliness of supportive care often determine outcomes, making it the dominant segment in the Dengue Treatment Market.

The Dengue Treatment Market reflects supportive care's dominance. Intravenous fluids, electrolytes, and monitoring equipment represent significant market segments, driven by hospitalisations during dengue outbreaks. Diagnostics also contribute, as early detection guides triage and treatment decisions. Rapid diagnostic tests for dengue NS1 antigen and IgM/IgG antibodies enable timely diagnosis and appropriate care.

Antiviral research is advancing, with candidates targeting viral replication and host immune responses. Vaccines represent a growing segment, with Qdenga (Takeda) and Dengvaxia (Sanofi) approved in several countries. However, vaccine access and uptake remain limited by cost, availability, and prior infection status considerations. As dengue burden grows and as innovation advances, supportive care is expected to remain the largest segment while antivirals and vaccines contribute to future growth in the Dengue Treatment Market.

People Also Ask

• How is dengue treated?
  Dengue is treated with supportive care, including rest, fluids, fever control, and, in severe cases, hospitalisation with intravenous fluids.

• Are there antivirals for dengue?
  No approved antivirals exist. Several candidates are in clinical trials, but supportive care remains the standard of treatment.

Tags: #Dengue #SupportiveCare #DengueTreatment #IntravenousFluids #Diagnostics #InfectiousDiseases